1. Introduction
===============

Ion channels have long been established as important regulators of the physiological functions of T lymphocytes and other immune cells \[[@B1-ijms-16-16880]\]. Potassium channels are required to maintain a hyperpolarized membrane potential necessary for sustaining the electrochemical driving force for Ca^2+^ ion entry upon T cell receptor stimulation \[[@B2-ijms-16-16880],[@B3-ijms-16-16880]\]. Targeting of potassium channels as a potential therapeutic strategy for autoinflammatory disorders can nowadays be viewed as an established concept, and the first attempts for clinical trials are ongoing \[[@B3-ijms-16-16880],[@B4-ijms-16-16880],[@B5-ijms-16-16880]\]. While the most intensively-studied potassium channels on lymphocytes are the voltage-gated K~V~1.3 and the Ca^2+^-activated K~Ca~3.1, we and others recently added members of the family of two-pore domain (K~2P~) potassium channels to the picture \[[@B4-ijms-16-16880]\]. K~2P~ channels are mainly voltage-independent K^+^ channels that are modulated by changes in pH, lipid metabolites or hypoxia \[[@B6-ijms-16-16880]\]. Human and murine T lymphocytes express the K~2P~ channels K~2P~3.1 (TASK1; KCNK3), K~2P~5.1 (TASK2; KCNK5) and K~2P~9.1 (TASK3; KCNK9) \[[@B1-ijms-16-16880],[@B4-ijms-16-16880],[@B7-ijms-16-16880]\]. *K~2P~3.1^−^*^/*−*^ mice are less susceptible to the induction of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and specific pharmacological blockers have a beneficial effect on clinical disease symptoms \[[@B8-ijms-16-16880],[@B9-ijms-16-16880]\]. Mice with a genetic deletion for *K~2P~9.1*, in direct comparison, showed a less pronounced protection against neuroinflammatory damage \[[@B8-ijms-16-16880]\]. In humans, all three K~2P~ channels are involved in T cell functions, such as proliferation or cytokine production \[[@B7-ijms-16-16880],[@B10-ijms-16-16880]\]. Especially expression of K~2P~5.1 is increased following T cell activation and in pathogenic T lymphocytes from patients with MS \[[@B10-ijms-16-16880]\] and rheumatoid arthritis (RA) \[[@B11-ijms-16-16880]\]. An especially pronounced upregulation of K~2P~5.1 was found on T lymphocytes located in the cerebrospinal fluid of MS patients and in the synovial fluid of RA patients, respectively \[[@B10-ijms-16-16880],[@B11-ijms-16-16880]\]. However, the further clinical translation of targeting K~2P~5.1 is at present not achievable due to a lack of highly selective K~2P~5.1-channel inhibitors demonstrating the need for mechanistical studies in established preclinical disease models. The impact of K~2P~5.1 on T lymphocyte function has been predominantly addressed in human cells, except basic physiological studies showing an involvement of K~2P~5.1 in human and murine T cell volume regulation \[[@B12-ijms-16-16880],[@B13-ijms-16-16880]\]. An involvement of K~2P~5.1 in murine immune cell function has been shown for B lymphocytes \[[@B14-ijms-16-16880],[@B15-ijms-16-16880]\]. K~2P~5.1 is expressed in WEHI-231 cells, a B lymphocyte cell line derived from murine lymphoma and primary murine B cells. K~2P~5.1 is upregulated upon B cell receptor stimulation and upon hypoxia-induced HIF-1α activation and regulates the influx of Ca^2+^ ions \[[@B14-ijms-16-16880],[@B15-ijms-16-16880]\]. It will be interesting to learn about in-depth immunological studies in the future to assess the functional importance of K~2P~5.1 for murine B cell function.

We here address the impact of K~2P~5.1 on murine T lymphocytes *in vitro* and in the MOG~35--55~ peptide-induced EAE model using *K~2P~5.1^−^*^/*−*^ mice. Furthermore, we perform pilot experiments to evaluate the possibility of performing pharmacological studies inhibiting K~2P~5.1 in the common marmoset, a non-human primate model for autoinflammatory disorders.

2. Results
==========

2.1. K~2P~5.1^−/−^ and Wild-Type Mice Show a Comparable Disease Course in the EAE Model
---------------------------------------------------------------------------------------

WT and *K~2P~5.1^−^*^/*−*^ mice were immunized with MOG~35--55~ peptide in order to induce EAE, an animal model mimicking aspects of MS. Both groups showed a comparable disease onset, disease maximum and overall disease course over 30 days ([Figure 1](#ijms-16-16880-f001){ref-type="fig"}A). We performed immunological and histological analysis of EAE mice in order to assess subtle changes not reflected by the clinical disease course. Splenocytes were isolated at disease maximum and restimulated with the same peptide stock used for immunization. No differences were observed for proliferation rates ([Figure 1](#ijms-16-16880-f001){ref-type="fig"}B,C, two independent methods) and for the production of the proinflammatory cytokines IFNγ, IL-2 and IL-17 ([Figure 1](#ijms-16-16880-f001){ref-type="fig"}D). Flow cytometric evaluation of CNS-invading immune cells revealed comparable numbers of CD4^+^ and CD8^+^ T lymphocytes and CD11b^+^ cells ([Figure 1](#ijms-16-16880-f001){ref-type="fig"}E). In agreement, histological evaluation displayed no significant changes for inflammatory infiltrates and demyelinated areas ([Figure 1](#ijms-16-16880-f001){ref-type="fig"}F). In summary, genetic deletion of *K~2P~5.1* resulted in no obvious effect in the EAE model, which is in contrast to the previously-published phenotypes of *K~2P~3.1^−^*^/*−*^ and *K~2P~9.1^−^*^/*−*^ mice \[[@B8-ijms-16-16880],[@B9-ijms-16-16880]\].

2.2. K~2P~5.1^−/−^ Mice Show No Obvious Alterations of the Immune System
------------------------------------------------------------------------

It has been reported before that human T lymphocytes upregulate K~2P~5.1 upon T cell receptor (TCR) stimulation \[[@B10-ijms-16-16880]\]. These results were corroborated, as human CD4^+^ T lymphocytes showed an approximately 60-fold upregulation of K~2P~5.1 ([Figure 2](#ijms-16-16880-f002){ref-type="fig"}A). In contrast, while murine lymphocytes also express K~2P~5.1, TCR stimulation only led to a non-significant trend towards an upregulation upon stimulation ([Figure 2](#ijms-16-16880-f002){ref-type="fig"}B). In the next step, we directly compared WT and *K~2P~5.1^−^*^/*−*^ mice. K~2P~5.1 protein was only detected on splenocytes and in kidney tissue of WT, but not of *K~2P~5.1^−^*^/*−*^ animals ([Figure 2](#ijms-16-16880-f002){ref-type="fig"}C). Naive splenocytes were stimulated, yielding no significant differences for cytokine levels of the proinflammatory T~H~1/T~H~17 cytokines IFNγ, IL-2, IL-17, the T~H~2 signature cytokine IL-4 and the regulatory cytokine IL-10 ([Figure 2](#ijms-16-16880-f002){ref-type="fig"}D). In accordance, proliferation rates and cell cycle stages of WT and *K~2P~5.1^−^*^/*−*^ T lymphocytes were comparable ([Figure 2](#ijms-16-16880-f002){ref-type="fig"}E). Furthermore, we addressed a potential influence of *K~2P~5.1* for immune cell development and the composition of splenocytes. Flow cytometric experiments revealed no obvious changes for spleen ([Figure 2](#ijms-16-16880-f002){ref-type="fig"}F) and thymus ([Figure 2](#ijms-16-16880-f002){ref-type="fig"}G). CD4^+^ T lymphocytes from WT and *K~2P~5.1^−^*^/*−*^ mice showed no significant alterations concerning T memory cell composition ([Figure 2](#ijms-16-16880-f002){ref-type="fig"}H) and cell surface markers indicative for cell activation (CD25, CD69) and migratory propensity (CD49d; [Figure 2](#ijms-16-16880-f002){ref-type="fig"}I).

![*K~2P~5.1^−^*^/*−*^ and WT mice showed a comparable clinical, immunological and histopathological phenotype in MOG~35--55~ EAE. (**A**) Upon MOG~35-55~ immunization, *K~2P~5.1^−^*^/*−*^ mice showed a comparable clinical disease course (left panel) and cumulative EAE score (right panel) over 30 days compared to wild-type mice (three independent immunizations, each *n* = 7--8); (**B**--**D**) Splenocytes from immunized mice were isolated at disease maximum (d16) and restimulated with 10 µg/mL MOG~35--55~ peptide. No differences were observed for (**B**,**C**) proliferation assessed by two independent methods and for (**D**) the production of IFNγ, IL-2 and IL-17 (*n* = 4); (**E**) Flow-cytometric evaluation of CNS-infiltrating immune cells isolated at disease maximum revealed no significant changes for numbers of CD4^+^, CD8^+^ and CD11b^+^ cells (*n* = 4); (**F**) Histological evaluation of inflammatory infiltrates (HE staining, **upper** panel) and demyelinated area (Luxol fast blue (LFB) staining, **lower** panel) showed no significant differences (*n* = 4--5). Scale bar (100 µm) accounts for all images. ns = not significant.](ijms-16-16880-g001){#ijms-16-16880-f001}

![T lymphocytes from *K~2P~5.1^−^*^/*−*^ mice displayed no obvious differences in immune cell function (**A**,**B**). (**A**) Human, but not (**B**) mouse CD4^+^ T lymphocytes show an upregulation of K~2P~5.1 (left panel: mean Δ*C*~t~ values; middle panel: all donors are displayed separately; right panel: relative expression); (**C**) K~2P~5.1 expression can be detected by Western blotting in splenocytes and kidney tissue from wild-type, but not from *K~2P~5.1^−^*^/*−*^ (ko) mice (representative examples); (**D**) WT and *K~2P~5.1^−^*^/*−*^ splenocytes show no differences in cytokine production (*n* = 6); (**E**) No significant differences were observed for proliferation rates from WT and *K~2P~5.1^−^*^/*−*^ T lymphocytes (**left** panel: proliferation assay; **right** panel: flow cytometry-based assessment of cell cycle stages; *n* = 8); (**F**) Splenocytes from WT and *K~2P~5.1^−^*^/*−*^ display a comparable immune cell composition (*n* = 6); (**G**) WT and *K~2P~5.1^−^*^/*−*^ thymi are comparable concerning proportions of double-negative, double-positive and CD4^+^/CD8^+^ single-positive cells (*n* = 4, one representative example is shown); (**H**,**I**) CD4^+^ T lymphocytes from WT and *K~2P~5.1^−^*^/*−*^ mice show no significant alterations concerning (**H**) memory cell composition (**I**) and activation and migration markers (*n* = 5). ns = not significant; **\*\****p* \< 0.05.](ijms-16-16880-g002){#ijms-16-16880-f002}

2.3. Compensatory Upregulation of K~2P~3.1 and K~V~1.3 in K~2P~5.1^−/−^ T Lymphocytes
-------------------------------------------------------------------------------------

Several potassium channels have been shown to be expressed in murine T lymphocytes \[[@B1-ijms-16-16880]\]. While these channels display unique properties, such as diverse expression patterns, biophysical properties or signaling pathways, they also share basic principles, as they regulate Ca^2+^ influx by setting the membrane potential, important for downstream pathways \[[@B16-ijms-16-16880]\]. Therefore, we searched for a compensatory upregulation of other known potassium channels in *K~2P~5.1^−^*^/*−*^ T lymphocytes. Indeed, K~2P~3.1 was upregulated on both CD4^+^ and CD8^+^ T lymphocytes, and K~V~1.3 was upregulated on CD4^+^ T lymphocytes ([Figure 3](#ijms-16-16880-f003){ref-type="fig"}A). We performed electrophysiological measurements to assess the functional contribution of K~2P~3.1 and K~V~1.3 upon *K~2P~5.1* deletion. No significant differences were observed for the membrane potential, pointing towards a comparable contribution of the whole-cell potassium outward current ([Figure 3](#ijms-16-16880-f003){ref-type="fig"}B). Furthermore, we applied specific pharmacological blockers for K~2P~3.1 (A293) and K~V~1.3 (ShK) channels and compared the current reduction in stimulated WT *versus* *K~2P~5.1^−^*^/*−*^ CD4^+^ T lymphocytes. Channel blockers had a significantly higher impact on *K~2P~5.1^−^*^/*−*^ cells, indicating a functional upregulation of K~2P~3.1 and K~V~1.3 on *K~2P~5.1^−^*^/*−*^ T lymphocytes ([Figure 3](#ijms-16-16880-f003){ref-type="fig"}C).

###### 

*K~2P~5.1* deletion results in a compensatory upregulation of K~2P~3.1 and K~V~1.3. (**A**) Relative quantification of unstimulated and stimulated WT and *K~2P~5.1^−^*^/*−*^ CD4^+^ and CD8^+^ T lymphocytes for the expression of *K~2P~3.1*, *K~2P~9.1*, *K~V~1.3* and *K~Ca~3.1* (*n* = 5--6); (**B**) Electrophysiological assessment of the resting membrane potential of unstimulated CD4^+^ T lymphocytes (*n* = 10); (**C**) Voltage steps from −80 to +40 mV for 500 ms were used to record outward currents in stimulated WT and *K~2P~5.1^−^*^/*−*^ CD4^+^ T lymphocytes. Current reduction after application of the K~2P~3.1 inhibitor A293 (10 µM) and the K~V~1.3 inhibitor Shk (10 nM) (*n* = 4) is shown; (**D**) Naive WT and *Task2^−^*^/*−*^ CD4^+^ T lymphocytes were stimulated for 10 min either with CD3/CD28 antibodies or PMA followed by cell lysis and Western blot analysis with antibodies against phosphorylated Zap70 (p-Zap70, left panel) and ERK1/2 (right panel). Representative examples (upper panel) and quantitative evaluation (lower panel, *n* = 4) are shown; (**E**) Calcium imaging experiments using Fura-2 in WT and *Task2^−^*^/*−*^ CD4^+^ T lymphocytes were performed under two conditions: T cell-receptor crosslink (CD3-X) in 2 mM Ca^2+^ (upper panel) or application of thapsigargin (TG) for intracellular Ca^2+^ store depletion in 0 mM Ca^2+^ prior to switching to 2 mM Ca^2+^ solution (lower panel). One out of five representative measurements are shown. ns = not significant; \*\* *p* \< 0.05.
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2.4. K~2P~5.1^−/−^ T Lymphocytes Display No Alterations in TCR-Dependent Signaling Pathways
-------------------------------------------------------------------------------------------

Activation via the T cell receptor initiates the activation of multiple signaling pathways involving tyrosine phosphorylation cascades and Ca^2+^-dependent pathways \[[@B16-ijms-16-16880]\]. We chose two key signaling enzymes involved in early (Zap70) and late events (ERK1/2) after TCR activation and assessed protein phosphorylation by specific antibodies. No significant differences were observed after TCR activation for Zap70 and ERK1/2 and after direct activation of downstream pathways by PMA for ERK1/2 ([Figure 3](#ijms-16-16880-f003){ref-type="fig"}D). Furthermore, Ca^2+^ imaging measurements using the Ca^2+^-sensitive dye Fura-2 revealed no significant alterations ([Figure 3](#ijms-16-16880-f003){ref-type="fig"}E). These experiments underline that K~2P~3.1 and K~V~1.3 are able to fully compensate K~2P~5.1 on a functional level.

2.5. Common Marmoset T Lymphocytes Functionally Express K~2P~5.1
----------------------------------------------------------------

Our current findings demonstrate that *K~2P~5.1^−^*^/*−*^ mice show no obvious phenotype in autoimmune neuroinflammation due to a functional compensation by the potassium channels K~2P~3.1 and K~V~1.3. An alternative model for multiple sclerosis, EAE in the common marmoset (Callithrix jacchus), has been proposed especially for testing the efficacy of new potential drugs \[[@B17-ijms-16-16880],[@B18-ijms-16-16880]\]. However, only very few commercial toolkits specifically designed for marmosets are currently available, making immunological or ion channel research difficult. Due to species homologies, both human and murine assays might potentially work with marmosets, which we could indeed confirm for a number of them ([Table 1](#ijms-16-16880-t001){ref-type="table"}). Therefore, we were able to isolate marmoset CD4^+^ T lymphocytes and to stimulate them with phytohemagglutinin (PHA), leading to a significant upregulation of K~2P~5.1 channels ([Figure 4](#ijms-16-16880-f004){ref-type="fig"}A). Expression of K~2P~5.1 on protein level could also be confirmed by flow cytometric measurements for CD4^+^ and CD8^+^ T cells ([Figure 4](#ijms-16-16880-f004){ref-type="fig"}B). Application of the K~2P~5.1 inhibitor quinidine led to a reduced proliferation rate of marmoset T cells, hinting towards a functional relevance of K~2P~5.1 for marmoset T lymphocytes ([Figure 4](#ijms-16-16880-f004){ref-type="fig"}C). As the next step, we aimed to detect K~2P~5.1-expressing lymphocytes in EAE lesions in the common marmoset, which were characterized by HE, CD3 and Luxol fast blue (LFB) staining ([Figure 4](#ijms-16-16880-f004){ref-type="fig"}D). However, available anti-K~2P~5.1 antibodies provided no positive signals in paraffin-embedded tissue; hence, we have not been able to address this question due to technical limitations so far. Using cryo-fixed tissue of naive marmosets, we found positive signals for several K~2P~ channels (K~2P~2.1, K~2P~5.1, K~2P~9.1, but not K~2P~3.1) underlining the fact that this channel group might also be of functional importance in the marmoset brain. In summary, these results provide the first hint that marmosets might be of use for K~2P~ channel-related neuroimmunological research.

ijms-16-16880-t001_Table 1

###### 

Evaluation of commercial kits for marmoset research.

  Commercial Kit                           Company                   Functional   Not Functional
  ---------------------------------------- ------------------------- ------------ ----------------
  CD4 non-human primate MACS kit           Miltenyi Biotec           X            
  CD8 non-human primate MACS kit           Miltenyi Biotec                        X
  Mouse anti-human CD4 antibody (RPA-T4)   BioLegend                 X            
  Mouse anti-human CD8 antibody (RPA-T8)   BioLegend                 X            
  Human CD3/CD28 microbeads                Life Technologies                      X
  Mouse CD3/CD28 microbeads                Life Technologies                      X
  Phytohemagglutinin                       Sigma-Aldrich             X            
  ATP Assay                                PerkinElmer               X            
  Rabbit anti-human/mouse K~2P~5.1         Sigma-Aldrich             X            
  Cytokine flow cytomix                    BenderMed Systems                      X
  Human ELISA IFNγ, IL-2                   eBioscience, RD Systems                X
  Mouse ELISA IFNγ, IL-2                   eBioscience, RD Systems                X
  Human RT-PCR primers                     Applied Biosystems        X            
  Quinidine                                Sigma-Aldrich             X            

Different commercial kits were evaluated with marmoset cells and are marked either as functional or as non-functional ("X" are set when applicable). See the [Experimental Section](#sec4-ijms-16-16880){ref-type="sec"} for further details.

![Expression of K~2P~5.1 channels in immune cells and CNS neurons in the common marmoset. (**A**) RT-PCR experiments show that CD4^+^ T lymphocytes from the common marmoset express *K~2P~5.1* in RT-PCR experiments, which is upregulated upon stimulation with PHA (*n* = 3); (**B**) CD4^+^ and CD8^+^ T lymphocytes express K~2P~5.1 protein as assessed by flow cytometry (one representative example out of three is shown); (**C**) The K~2P~5.1 inhibitor quinidine (20 µM) reduces the proliferation of stimulated marmoset CD4^+^ T lymphocytes (*n* = 3); (**D**) EAE lesions in the common marmoset characterized by HE, CD3 and LFB staining; (**E**) Brain samples from naive common marmosets were assessed by immunohistochemical staining for K~2P~2.1, K~2P~5.1 and K~2P~9.1. NeuN was used as a neuronal marker. The region of interest is displayed by HE staining on the right side. \* = *p* \< 0.05.](ijms-16-16880-g004){#ijms-16-16880-f004}

3. Discussion
=============

Previously, K~2P~5.1 channels were shown to play an important role for T cell activation, both under physiological circumstances and under autoinflammatory conditions. In contrast to human T lymphocytes, we here demonstrate that K~2P~5.1, despite its expression under basal conditions, is not upregulated upon stimulation in murine T cells. Obviously, K~2P~5.1 seems to play a more pronounced role in human than murine T lymphocytes. Species-dependent differences have been reported especially for voltage-dependent potassium channels before \[[@B3-ijms-16-16880]\]. Furthermore, genetic deletion of *K~2P~5.1* does not result in immune cell alterations *in vitro* or in the EAE model, most likely due to a compensatory upregulation of K~2P~3.1 and K~V~1.3 channels. These results were unexpected in light of previous results obtained from *K~2P~3.1^−^*^/*−*^ and *K~2P~9.1^−^*^/*−*^ mice that showed no compensatory upregulations of other channels, resulting in differences in immune cell functions. K~2P~5.1 was firstly discovered nearly 20 years ago \[[@B19-ijms-16-16880]\]. It was initially named TWIK-related acid-sensitive K^+^ channel 2, due to the similar sensitivity to extracellular pH values compared to K~2P~3.1 \[[@B20-ijms-16-16880]\]. However, it is now clear that K~2P~5.1 does not belong to the TASK, but rather to the phylogenetically- and structurally-different TALK subfamily of K~2P~ channels \[[@B21-ijms-16-16880],[@B22-ijms-16-16880]\]. Despite obvious functional analogies of K~2P~3.1, K~2P~9.1 and K~2P~5.1, these molecular biological details should be kept in mind in order to avoid jumping to conclusions based on observations from one K~2P~ channel to another.

Different research groups have previously obtained experimental data from *K~2P~5.1^−^*^/*−*^ mice, which are often regarded to be more reliable than pharmacological studies due to a limited specificity of available K~2P~5.1 blockers. Besides its expression in immune cells, K~2P~5.1 function has been implicated in a variety of different cells and tissues, such as specific neuronal populations in the CNS, kidney epithelial cells or chondrocytes \[[@B21-ijms-16-16880],[@B23-ijms-16-16880]\]. Early reports using newly generated *K~2P~5.1^−^*^/*−*^ mice described a contribution of K~2P~5.1 to cell volume regulation in mouse renal proximal tubule cells \[[@B24-ijms-16-16880],[@B25-ijms-16-16880]\]. An involvement of K~2P~5.1 channels in regulatory volume decrease has subsequently been demonstrated for additional cell types using pharmacological approaches \[[@B24-ijms-16-16880],[@B26-ijms-16-16880]\], while direct proof comparing WT and *K~2P~5.1^−^*^/*−*^ mice was only provided for *K~2P~5.1^−^*^/*−*^ lymphocytes \[[@B13-ijms-16-16880]\]. K~2P~5.1 is involved in proximal tubule bicarbonate reabsorption, and *K~2P~5.1^−^*^/*−*^ mice show a secondary metabolic acidosis and hypotension \[[@B27-ijms-16-16880]\]. In the CNS, K~2P~5.1 channel expression is normally restricted to respiratory center nuclei in the brainstem, and *K~2P~5.1^−^*^/*−*^ mice show disturbed respiratory responses to hypoxia and hypercapnia \[[@B28-ijms-16-16880],[@B29-ijms-16-16880],[@B30-ijms-16-16880]\]. However, under pathophysiological acute ischemic conditions in an experimental model of cerebral ischemia, K~2P~5.1 is strongly upregulated on neurons where it supposedly contributes to the induction of neuronal apoptosis. Accordingly, *K~2P~5.1^−^*^/*−*^ mice had significantly reduced infarct volumes \[[@B31-ijms-16-16880]\]. Interestingly, the functional contribution of K~2P~5.1 expression on T lymphocytes was evaluated for post-ischemic inflammatory reactions that deteriorate the experimental outcome in the used mouse model of transient middle cerebral artery occlusion. Adoptive transfer experiments of wild-type and *K~2P~5.1^−^*^/*−*^ T lymphocytes into *Rag1^−^*^/*−*^ mice prior to stroke induction showed no impact of K~2P~5.1 expression on T lymphocytes on stroke outcomes. These previous findings are in agreement with our current study showing that genetic deletion of *K~2P~5.1* is compensated by other potassium channels.

Our current findings show that the value of the classical murine MOG~35--55~-EAE model in C57BL/6 mice might be limited for a further functional and pharmacological assessment of K~2P~5.1 channels. The common marmoset displays a higher genetic homology with humans than mice (85% *versus* 40%) and might therefore be better suited as a future animal model for immunological assessment of the K~2P~5.1 channel-related pathology. Therefore, we conducted pilot experiments in the common marmoset providing first hints that marmosets might be worth further investigations in this context.

4. Experimental Section {#sec4-ijms-16-16880}
=======================

4.1. Experimental Autoimmune Encephalomyelitis Induction and Evaluation
-----------------------------------------------------------------------

All animal experiments were approved by the local authorities (Landesamt für Natur, Umwelt und Verbraucherschutz NRW, Kirchhundem, Germany) and conducted according to the German law of animal protection. EAE was induced by immunization of 10--12-week-old female C57BL/6 (Charles River, Sulzfeld, Germany) or *K~2P~5.1^−^*^/*−*^ mice \[[@B24-ijms-16-16880]\] with 200 µg MOG~35--55~ peptide (Biotrend, Cologne, Germany). MOG peptide was added to complete Freund's adjuvants to obtain a 1-- mg/mL emulsion, which was injected subcutaneously at the flank of deeply anesthetized mice. Pertussis toxin was injected on the day of immunization and 2 days later at a dose of 400 ng (Alexis, San Diego, CA, USA). Scoring was done by a blinded observer using the following score system: 0, no abnormality; 1, limp tail tip; 2, limp tail; 3, moderate hind-limb weakness; 4, complete paralysis of one hind-limb; 5, mild paraparesis; 6, paraparesis; 7, paraplegia; 8, tetraparesis; 9, quadriplegia or pre-moribund state; and 10, death. Animals with a score higher than 7 were euthanized, and the last score observed was included in the analysis until the end of the experiment. The cumulative EAE score was calculated by summing up each individual daily scores divided by the number of days.

4.2. Murine Cell Isolation and Culture
--------------------------------------

Spleens were isolated from age- and sex-matched mice (aged 8--12 weeks) or from immunized EAE mice at disease maximum (d15). Tissue was homogenized and strained through a 40 µm nylon filter. The homogenates were rinsed with washing medium (DMEM containing 1% FCS, 1% glutamine, 1% antibiotics) and shortly resuspended in erythrocyte lysis buffer (150 mM NH~4~Cl, 10 mM KHCO~3~, 0.1 mM EDTA; pH 7.3). For some experiments, thymic cells were isolated from 4--6 week old mice in a comparable fashion. Immune cell subsets were isolated using appropriate magnetic bead-based separation kits (CD4^+^ or CD8^+^ T cell isolation kit II, Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were cultured in DMEM containing 10 mM HEPES, 25 μg/mL gentamicin, 50 μM β-mercaptoethanol, 5% FCS, 2 mM glutamine and 1% non-essential amino acids (Cambrex, Verviers, Belgium).

4.3. Immunological Analysis
---------------------------

Splenocytes were isolated either from naïve mice or from EAE mice at disease maximum. Cells were either stimulated with anti-CD3 (2 µg/mL) and anti-CD28 (1 µg/mL) antibodies or restimulated with 10 µg/mL MOG~35--55~ peptide. IFNγ, IL-17A, IL-2, IL-4 and IL-10 levels were assessed by enzyme-linked immunosorbent assay (ELISA, Ready-SET-Go! ELISA kit; eBioscience, Frankfurt, Germany).

For evaluation of cell proliferation, the amount of ATP in the supernatant after cell lysis was assessed as an indicator of cell proliferation using an ATPlite luminescence ATP detection assay system (PerkinElmer, Waltham, MA, USA) according to the manufacturer's instructions and as described previously \[[@B32-ijms-16-16880]\]. Luminescence was measured on an Infinite 200 PRO multimode microplate reader (Tecan, Männedorf, Switzerland), and the splenocyte stimulation index was calculated as cell abundance with stimulation divided by cell abundance without stimulation. Alternatively, 1 µCi of \[3H\]thymidine (Amersham, Piscataway, NJ, USA) was added for the final 24 h. Radioactivity was measured on a β-scintillation counter (TopCount NXT; PerkinElmer, Rodgau-Jügesheim, Hessen, Germany).

For flow cytometric evaluation of CNS-invading cells, mice were perfused transcardially with PBS to diminish contamination by leukocytes located within blood vessels. CNS tissue was dissociated mechanically, and mononuclear cells from the interface of a 30%--50% Percoll (GE Healthcare, Little Chalfont, Buckinghamshire, UK) density centrifugation gradient were further analyzed by flow cytometry. Cells were evaluated on a Gallios Flow Cytometer (Beckman Coulter, Krefeld, Germany).

For some experiments, peripheral blood mononuclear cells were obtained from the EUPRIM-NET program and used as described in [Table 1](#ijms-16-16880-t001){ref-type="table"}.

4.4. Immunohistochemical Analysis
---------------------------------

For histological evaluation of EAE, mice were transcardially perfused with PBS. Spinal cords were carefully excised and embedded in Tissue-Tek OCT optimal cutting temperature compound (Sakura Finetek, Torrance, CA, USA). To ensure that the same lumbar region was analyzed for all mice, transverse cryosections (10 mm thick) were cut and stained with HE or LFB according to standard protocols. Ten tissue sections separated by at least 40 mm were analyzed from five animals per group. Histological quantifications were assessed by an investigator blinded to treatment groups using an Axiophot 2 microscope (Carl Zeiss Microscopy, Jena, Germany) equipped with a charge-coupled device camera; images were analyzed with MetaVue research imaging software (Molecular Devices, Sunnyvale, CA, USA).

For fluorescence staining of marmoset brain slices, cryosections were postfixed in 4% paraformaldehyde for 10 min and incubated in blocking solution (PBS containing 5% bovine serum albumin, 1% donkey serum and 0.2% Triton X-100 surfactant). Slices were then incubated with antibodies against rabbit anti-mouse K~2P~3.1, rabbit anti-mouse K~2P~5.1, rabbit anti-mouse K~2P~9.1, rabbit anti-mouse K~2P~2.1 or rat anti-mouse NeuN (Millipore, Schwalbach, Germany) overnight at 4 °C. The secondary antibodies were Cy3 donkey anti-rabbit and Cy2 goat anti-rat (Dianova, Hamburg, Germany). Tissue was mounted with Prolong Gold antifade reagent containing DAPI (Life Technologies, Carlsbad, CA, USA). Negative controls were obtained by omitting either the primary or secondary antibody and revealed no detectable signal on subsequent analysis (data not shown).

4.5. Isolation of Human CD4^+^ T Lymphocytes
--------------------------------------------

PBMC were isolated from peripheral blood of healthy individuals by density centrifugation using lymphocyte separation medium (Axis-Shield) according to the manufacturer's instructions. CD4^+^ T lymphocytes were isolated using the CD4^+^ T cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) and stimulated by anti-human CD3 (OKT3, 2 µg/mL) and anti-human CD28 (28.2, 1 µg/mL, eBioscience, Frankfurt, Germany).

4.6. Flow Cytometry
-------------------

Flow cytometric analysis was performed using the following anti-mouse antibodies (all from BioLegend, San Diego, CA, USA): anti-CD3 FITC (clone 17A2), anti-CD4 APC (RM4-5), anti-CD8a AF700 (53-6.7), anti-CD11b PE (M1/70), anti-CD19 PE/Cy7 (6D5), CD44 PE/Cy7 (IM7), CD62L PE (MEL-14), CD49d (R1-2), CD25 PE/Cy7 (PC61) and CD69 PE (H1.2F3). Cells were analyzed with a Gallios flow cytometer (Beckman Coulter, Krefeld, Germany).

4.7. Real-Time PCR
------------------

RNA was purified using TRIzol reagent (Life Technologies, Carlsbad, CA, USA), and RT-PCR was performed following standard protocols using TaqMan Gene Expression Assays (Life Technologies, Carlsbad, CA, USA) with specific primers for human K~2P~5.1 (Hs00186652_m1), mouse K~2P~3.1 (Mm04213388_s1), K~2P~5.1 (Mm00498900_m1), K~2P~9.1 (Mm02014295_s1), K~V~1.3 (Mm00434599_s1), K~Ca~3.1 (Mm00464586_m1) and eukaryotic 18S RNA (Hs9999901_s1). Data were calculated using Δ*C*~t~, ΔΔ*C*~t~ and relative quantification (2^−ΔΔ*C*t^).

4.8. Electrophysiology
----------------------

Whole-cell electrophysiology was performed using isolated CD4^+^ T lymphocytes. All measurements were conducted in the whole-cell configuration of the patch-clamp technique 24 h after cell stimulation. Recording pipettes were filled with a solution containing (in mM): KCl, 140; HEPES, 5; MgCl~2~, 2; EGTA, 1; Na~2~-ATP, 1; GTP, 0.1; cAMP, 0.1. pH was set to 7.2 with KOH. Cells were continuously superfused with a bath solution containing (in mM): NaCl, 135; KCl, 5.4; HEPES, 5; MgCl~2~, 1; CaCl~2~, 1.8; and glucose, 10. pH was set to 7.4 with NaOH. Recordings were performed with an EPC-10 amplifier (HEKA Elektronik, Lambrecht, Germany). The resistance of the glass pipettes was 3--4 MΩ. The access resistance was in the range of 7--14 MΩ, and a series resistance compensation of more than 40% was used routinely. Measurements were either performed in the current or voltage clamp mode. The voltage protocol consisted of a depolarizing rectangular 500 ms pulse to +40 mV. A liquid junction potential of about 4 mV was measured and taken into account. Recordings were digitally analyzed using the Fitmaster software (HEKA Elektronik, Lambrecht, Germany).

4.9. Western Blots
------------------

For signaling analysis, cells were stimulated with anti-mouse CD3 (clone 145-2C11, 10 µg/mL) and anti-mouse CD28 (clone 37.51, 1 µg/mL, both eBioscience, Frankfurt,Germany) or 10 ng/mL PMA (Sigma-Aldrich, St. Louis, MO, USA) for 4 min. Cells were lysed for 30 min on ice in 30 µL lysis buffer (1% NP-40, 10% *N*-dodecyl-β-[d]{.smallcaps}-maltoside, 1 mM sodium monovanadate, 1 mM phenylmethanesulfonyl fluoride (PMSF), 50 µM TRIS, 10 mM NaF, 10 mM EDTA and 165 mM NaCl). Following 10 min of centrifugation (18,407× *g*, 4 °C), the supernatant was mixed with 7.5 µL sample buffer (20 mM TRIS, 10% glycerol, 0.05% bromophenol blue and 1% SDS) and heated for 5 min at 99 °C. Proteins were separated using a 10% SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked with 5% dry milk and probed with rabbit anti-murine K~2P~5.1 (Sigma-Aldrich), rabbit anti-p-ERK1/2 (Cell Signaling) or rabbit anti-p-Zap70 (Cell Signaling) diluted in 5% BSA and incubated overnight at 4 °C. Secondary antibody against rabbit was horseradish-peroxidase conjugated (Santa Cruz Antibodies, Dallas, TX, USA). The antibody reaction was detected by enhanced chemiluminescence reaction (ECL, Amersham Biosciences, Amersham, UK), and quantification was done using ImageJ software (V1.46r, originally developed by Wayne Rasband, now available as public domain). Anti-β-actin (Sigma-Aldrich, St. Louis, MO, USA) was used for loading controls.

4.10. Calcium Imaging
---------------------

For calcium imaging experiments, T lymphocytes were isolated as described above. Analysis was performed in HEPES buffer containing 120 mM NaCl, 2.5 mM KCl, 1.25 mM NaH~2~PO~4~, 30 mM HEPES, 2 mM MgSO~4~, 10 mM glucose, pH 7.25, and osmolality was set to 305 mOsm/kg. Cells were loaded with 5 μM Fura-2 AM (Invitrogen, Karlsruhe, Germany) for 30 min at 37 °C. Fluorescence was measured with a TECAN infinite M200Pro fluorimeter (Tecan Group Ltd., Männedorf, Switzerland). Excitation was alternated between 340 and 380 nm, and emission was measured at 509 nm every 3 s. Either hamster anti-mouse CD3 and goat anti-hamster IgG antibodies (eBioscience, Frankfurt, Germany) or thapsigargin (0.1 µM; Sigma-Aldrich, St. Louis, MO, USA) were used for stimulation.

4.11. Statistical Analysis
--------------------------

All results are presented as the mean ± SEM. Statistical analysis was performed using Student's *t*-test in the case of normally-distributed data or a Mann--Whitney test for parametric data without normality and equality of variance, as well as for non-parametric datasets. A one-way ANOVA with a Bonferroni *post hoc* test was used in the case of multiple comparisons for parametric data, and a Kruskal--Wallis ANOVA was used for non-parametric data. *p*-values \< 0.05 were considered statistically significant.

5. Conclusions
==============

Human T lymphocytes express K~2P~5.1 channels regulating T cell functions under physiological and pathological conditions. In contrast, *K~2P~5.1^−^*^/*−*^ mice display no significant alterations concerning T cell cytokine production, proliferation rates, surface marker molecules or signaling pathways resulting in an unaltered disease phenotype in an animal model of autoimmune inflammation. A compensatory upregulation of the potassium channels K~2P~3.1 and K~V~1.3 is responsible to counterbalance the deletion of *K~2P~5.1*. Preliminary experiments hint towards a potential use of the marmoset model for future research efforts as an alternative animal model.
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